OHSU researchers co-leading the landmark SOUL trial have demonstrated that oral semaglutide reduces the risk of heart failure events in people with type 2 diabetes — a finding announced by OHSU that positions the institution at the forefront of GLP-1 receptor agonist cardiovascular outcomes research. The oral formulation's efficacy in this high-risk subgroup removes a key uncertainty that has limited prescriber confidence in non-injectable semaglutide for cardioprotection.

The significance of the oral delivery mechanism cannot be overstated. While injectable semaglutide (marketed as Ozempic and Wegovy) has dominated both clinical conversations and media coverage, a substantial portion of patients — particularly older adults managing multiple chronic conditions — resist self-injection. Oral semaglutide (Rybelsus) has had slower commercial uptake partly because its cardiovascular benefit profile was less established. The SOUL trial closes that evidence gap and gives providers a compelling reason to offer the oral option to injection-averse patients with T2D and heart failure risk.

Oregon providers should recognize the prescribing implications. The overlap between T2D and heart failure is substantial — roughly one in three T2D patients has some degree of heart failure — and many of those patients are managed by primary care, not cardiology. Oregon CCOs will need to evaluate oral semaglutide coverage in light of this data, balancing per-unit drug costs against the potential for reduced heart failure hospitalizations that cost the system far more. OHSU's role in generating this evidence also strengthens the institution's reputation as a site for future cardiovascular and metabolic trials, which brings research dollars and clinical expertise to the state.

Watch for whether payers update coverage criteria to include heart failure risk reduction as an approved indication for oral semaglutide.